Physician profile
John Michael Pierce
NPI 1619558475
$784.75
in general payments reported to CMS, 2019-2025
12 companies · $785 in 2025
The $785 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.58 |
| Education | $112.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $170.59 | 2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $164.92 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $134.65 | 2025 | |
| Novartis Pharmaceuticals Corporation | $109.24 | 2025 | |
| Leo Pharma INC. | $54.10 | 2025 | Anzupgo, Spevigo |
| Amgen INC. | $33.22 | 2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $31.84 | 2025 | Dupixent |
| Abbvie INC. | $26.83 | 2025 | |
| Botanix Sb INC | $16.90 | 2025 | Sofdra |
| Lilly USA, LLC | $14.94 | 2025 | Ebglyss, Taltz |
| Genzyme Corporation | $14.35 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.